ASTRO 2023

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on stereotactic radiotherapy for renal cell cancer. Dr. Nicholas Zaorsky discussed the potential synergistic and adverse effects of systemic therapy use with stereotactic ablative radiotherapy (SABR) in patients with metastatic RCC.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on stereotactic radiotherapy for renal cell cancer. Dr. Shankar Siva discussed technical considerations, response assessment, and challenging cases in primary renal stereotactic ablative radiotherapy (SABRT).

(UroToday.com)The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on stereotactic radiotherapy for renal cell cancer. Dr. Rana McKay discussed the multidisciplinary management of renal cell carcinoma (RCC) from the medical oncology perspective.

(UroToday.com) The 2023 ASTRO annual meeting included a session on exploring ethical and legal implications of artificial intelligence in medical practice, featuring a presentation by Dr. Rashimi Jaggard discussing artificial intelligence cybersecurity in healthcare.

(UroToday.com) The 2023 ASTRO annual meeting included a session on exploring ethical and legal implications of artificial intelligence in medical practice, featuring a presentation by Dr. Skyler Johnson discussing ethical considerations of artificial intelligence chat bots--ChatGPT and beyond.

(UroToday.com) The 2023 ASTRO annual meeting included a session on exploring ethical and legal implications of artificial intelligence in medical practice, featuring a presentation by Dr. Tony Quang discussing legal and regulatory implications of artificial intelligence in clinical oncology. Dr. Quang notes that there has been a massive uptick in artificial intelligence manuscripts over the last several years. As follows are the results of a PubMed search of “artificial intelligence and radiation oncology”:

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA was host to a session on stereotactic radiotherapy for renal cell cancer. Dr. Rohann Correa provided a primer on primary kidney stereotactic ablative radiotherapy (SABR).

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA was host to a session on patient-reported quality of life in prostate cancer. Dr. Abdenour Nabid discussed the results of an analysis of patient reported outcomes in high-risk prostate cancer patients with or without testosterone recovery following ADT.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on radiotherapy and the post-prostatectomy setting. Dr. Atallah Baydoun presented the results of an analysis evaluating post-prostatectomy risk stratification in the biochemical recurrence setting using transfer learning-based multi-modal artificial intelligence.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on radiotherapy for kidney cancer and the post-prostatectomy setting. Dr. Vivian Tan presented the results of an analysis of the International Radiosurgery Oncology Consortium of the Kidney (IROCK) evaluating the 5-year renal function outcomes following stereotactic ablative radiotherapy (SABR) for primary renal cell carcinoma.

The 2023 ASTRO annual meeting included a session on patient-reported quality of life in prostate cancer, featuring a presentation by Dr. Wee Loon Ong discussing a post-hoc analysis of the TROG 03.04 RADAR trial, specifically patient-reported urinary and bowel quality of life outcomes following external beam radiotherapy with or without high-dose-rate brachytherapy boost. Three previous clinical trials have shown that a brachytherapy boost to external beam radiotherapy improves biochemical control.

The 2023 ASTRO annual meeting included a session on patient-reported quality of life in prostate cancer, featuring a presentation by Dr. Simon Spohn discussing toxicity and patient reported quality of life after PSMA-PET and mpMRT-based focal dose escalated definitive radiotherapy in prostate cancer patients.

(UroToday.com) The 2023 ASTRO annual meeting included a session on patient-reported quality of life in prostate cancer, featuring a presentation by Dr. Gregory Alexander discussing conditional risk and predictive factors associated with late toxicity for prostate cancer patients treated with external beam radiotherapy alone in RTOG 0126. Given that patients with localized prostate cancer treated with radiotherapy alone have excellent outcomes, making quality of life and minimization of toxicities of great concern. The risk of developing toxicity may evolve with time from treatment which is of interest to patients seen in follow up. The primary objective of this study is to determine the conditional risk of grade 2+ gastrointestinal or genitourinary toxicity for patients treated with radiotherapy in the RTOG 0216 trial, which was a prospective randomized trial that randomized men with localized prostate cancer to two different radiotherapy schedules. A secondary objective was to determine risk factors associated with the development of late toxicities.

(UroToday.com) The 2023 ASTRO annual meeting included a session on patient-reported quality of life in prostate cancer, featuring a presentation by Dr. Priyamvada Maitre discussing late urinary toxicity and quality of life with curative radiotherapy for high-risk prostate cancer in the POP-RT randomized phase III trial. Whole pelvic radiotherapy showed better biochemical failure-free survival and metastasis-free survival than prostate-only radiotherapy in the phase III randomized POP-RT trial for high and very high-risk prostate cancer, albeit with higher RTOG grade 2 late urinary toxicity.¹ The trial design for POP-RT is as follows:

(UroToday.com) The 2023 ASTRO annual meeting included a session on patient-reported quality of life in prostate cancer, featuring a presentation by Dr. Atsunori Yorozu discussing health-related quality of life at five years for a randomized trial of tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- versus long-term androgen deprivation. Given that both arms have previously demonstrated similar efficacy and safety, the objective of the presentation at ASTRO 2023 was to describe the patient-reported health-related quality of life outcomes at five years from the TRIP/TRIGU0907 trial.

(UroToday.com) The 2023 ASTRO annual meeting included a session on exploring the ethical and legal implications of artificial intelligence in medical practice, featuring a presentation by Dr. Sushil Beriwal discussing artificial intelligence tools in radiation oncology clinical practice. Dr. Beriwal started by highlighting that artificial intelligence is the simulation of human intelligence processes by machines, especially computer systems, and the ability of computer algorithms to approximate conclusions based solely on input data. These systems work by:

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on radiotherapy for kidney cancer and the post-prostatectomy setting. Dr. Alan Dal Pra discussed the results of a secondary analysis of the phase 3 NRG/RTOG 0534 SPPORT trial evaluating the impact of testosterone recovery on clinical outcomes of patients treated with salvage radiotherapy and androgen suppression.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session discussing combined modality therapy for lymph node positive prostate cancer. Dr. Hala Borno discussed the current state of modern systemic therapy for advanced prostate cancer.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on radiotherapy for kidney cancer and the post-prostatectomy setting. Dr. Paul Nguyen presented FORMULA-509 (Facilitation Of Radiation Management Using Lupron Abiraterone & ARN-509), a multicenter randomized trial of post-operative salvage radiotherapy and 6 months of a GnRH agonist with either bicalutamide or abiraterone acetate and apalutamide.

(UroToday.com) The 2023 American Society for Radiation Oncology (ASTRO) 65^th Annual Meeting held in San Diego, CA between October 1^st and 4^th, 2023 was host to a session on radiotherapy for kidney cancer and in the post-prostatectomy setting. Dr. Anand Swaminath presented the final results of RADSTER, a prospective randomized pilot trial of stereotactic body radiotherapy (SBRT) versus radiofrequency ablation for the management of small renal masses.